L225P Mutation of ABCC8 Gene: A Case of Transient Neonatal Diabetes Mellitus with Thrombophilic Predisposition and Epilepsy

Francesca Silvestri1, Giulia Maiella2, Raffaella Scrocca3 and Francesco Costantino1

1Department of Pediatrics, Sapienza University of Rome, Italy
2Department of Pediatrics, Bambino Gesù Children’s Hospital, Italy

Keywords: Neonatal diabetes mellitus; ABCC8 mutation; Glybenclamide; Epilepsy

Case Report

A three-months-old baby was referred to emergency pediatric department of Policlinico Umberto I Institute, Rome, because of intermittent ipsilateral clonus to the upper and lower right limbs, in flexion and internal rotation, slight reduction of the rotation of the head to the right, slight reduction in speed and amplitude of the movements of the upper right limb with closed hand. There was asymmetry of the right emiface, slightly closed eye and reduced motility of mouth.

He was born at 39 gestational weeks after a complicated pregnancy by single umbilical artery and placental senescence diagnosed at 24th week. Birth weight: 2470 g, length: 48 cm and Apgar score: 9 and 10. There was family history for autoimmune diseases and ischemic accidents but none for diabetes and seizures.

On physical examination the infant was awake, well hydrated. Respiratory rate: 34/min, Heart rate 133 bpm, temperature 36.9°C, Blood pressure: 65/45 mmHg.

The first-line findings: Ph: 7.4, HCO3−: 19 mEq/L, pCO2: 41 mmHg, K+: 4.8 mmol/L, Na: 135 mmol/L, Cl: 94 mmol/L, Ca: 10.8 mg/dL, Glucose: 413 mg/dL, Lactic acid: 1.9 mmol/L.

Epilepsy was unresponsive to intravenous midazolam (0.1 mg/kg), so he received increasing doses of Phenobarbital and Phenytoin with an effective management of epilepsy.

Hyperglycaemia was initially treated with intravenous saline solution and ultrarapid insulin. After, he received subcutaneous insulin with good glycaemic control.

Figure 1: Small area of restricted diffusion in the white matter areas of the corona radiate on the left front seat, referred to an uncertain hypoxic-ischemic acute suffering of parenchyma in acute phase.

EEG showed partial motor epilepticus status with left occipital starting. Blood culture and lumbar puncture were negative. HbA1c: 117 mmol/mol, Apo B1: 1.28 (0.58-1.13), Triglycerides: 297 mg/dl.
(37-278), Total Cholesterol: 239 mg/dl (109-204), LDL: 156 mg/dl (35-125), D dimer: 476 ng/ml.

The stool following breastfeeding was normal, showing no pancreatic exocrine deficiency.

Thrombophilia screening showed the following abnormal results: Protein C: 42 (n.v 70-115), Protein S: 54 (n.v 64-124), Factor II: 35-125), D dimer: 476 ng/ml.

Brain magnetic resonance imaging (MRI) showed a small area of restricted diffusion in the white matter areas of the corona radiate on the left front seat, referred to an uncertain hypoxic-ischemic acute suffering of parenchyma, disappeared at the following MRI, after six days (Figures 1 and 2).

Molecular biology exam performed on DNA examining KCNJ11 (Kir 6.2), INS and ABCC8 (SUR1) genes. The two exons of the gene INS, exon of the gene KCNJ11 and 39 exons of the ABCC8 gene were amplified by PCR and sequenced by capillary electrophoresis. The sequences are inclusive of intron-exon junctions. It was found the mutation in the heterozygous CTCGGCC in position 674 of the gene ABCC8, with substitution of Leucine 225 in Proline (L225P). This is a de novo mutation.

Parents gave their informed consent prior the switching to Glybenclamide. Was administered glargine insulin 6-4 IU and regular one 0.3 -0.4 IU/kg at meals for 17 days. After molecular genetics results we had introduced an oral suspension of insulin secretagogue, Glybenclamide for four weeks:
- 1st week 6 IU Glargine + 0.3 mg/kg/day of Glybenclamide.
- 2nd week 4 IU Glargine + 0.4 mg/kg/day of Glybenclamide.
- 3rd week 3IU Glargine + 0.4 mg/kg/day of Glybenclamide.
- 4th week 2/1 IU Glargine + 0.4 mg/kg/day Glybenclamide.

After 2 months of treatment with Glybenclamide, it was started decal age because of reduced demand from 0.4 mg/kg/day to 0.05 mg/kg/day and after 13 months treatment was ended.

Discussion

The etiology of NDM differs from insulin dependent diabetes mellitus Type 1 (DM1). NDM is monogenic, has not anti-insulin, anti-islet cell and anti-glutamic acid decarboxylase antibodies.

Various syndromes and genetic diseases have been reported in PNDM. Our patient has no signs of any syndromes [1-12].

A subgroup of mutations cause severe clinical profile characterized by delayed development of motor, intellectual and social skills, muscle weakness, epilepsy, facial dimorphisms and Neonatal Diabetes (DEND syndrome) [13-15].

Approximately 20% of cases with mutation in KCNJ11 and ABCC8 have extra pancreatic features, the most severe of which is DEND syndrome. Studies suggest that the severity of the clinical phenotype reflects the extent of the reduction of the channel ATP sensitivity [16].

Thus, patient affected by mutations that produce a larger increase in K-ATP are more likely to develop DEND syndrome [14,15].

Our child did not show any intellectual-cognitive and motor deficits but only a partial motor functional limitation linked to cerebral ischemia, so we have excluded DEND syndrome for differential diagnosis, but we hypothesized that stroke and mutation of the K ATP channels caused seizures in sinergy.

We would like to focus our attention on epilepsy crisis, which were the first clinical sign to manifest without diabetic ketoacidosis neither neurological delay but the result of a series of concomitant factors such as hyperglycemia, familial hypercholesterolemia, MTHFR and prothrombin gene mutation predisposing to thrombotic risk.

EEG was performed on the first day and the following days of hospitalization. It showed an epileptic alteration and he was treated with phenobarbital (15 mg/twice a day). There are K ATP channels in the brain so, if they are mutated could cause an elongation of depolarization time with alterations of the electrical conduction.

Treatment with Glybenclamide improved glycemic control, as pointed out by HbA1c levels (median HbA1c pre-Glybenclamide 12.9% (117 mmol/mol), post-transition HbA1c 6.3% (45 mmol/mol), without increase of hypoglycemic episodes. Interestingly, the patient enhanced his production of insulin, requiring progressively smaller doses of Glybenclamide until he stopped treatment at 19 months of age. HbA1c after 3 months from the end of therapy was 4.7% (28 mmol/mol). Our patient, even if showing a mutation already described in literature as PNDM [17,18] to date, after 12 months from the end of therapy does not require any treatment for diabetes. Considering the excellent glycemic control and HbA1c values, we made diagnosis of TNDM.

As previously described in literature, the mutation of the gene ABCC8 (L225P), is mostly responsible of PNDM. We affirm that this mutation doesn't always decode the same phenotype. Our patient certainly suffered of TNDM because after 13 months he was also weaned off Glybenclamide and is currently under an optimal glycemic control. However, our patient is the first case of TNDM induced by substitution of L225P in ABCC8 gene reported in literature [19-28].

Acknowledgement

The contribution of Prof. Barbetti's laboratory to the identification of the mutation is gratefully acknowledged.
References

1. Aguilar-Bryan L, Bryan J (2008) Neonatal diabetes mellitus. Endocr Rev 29: 265-291.
2. De León DD, Stanley CA (2011) Permanent Neonatal Diabetes Mellitus.
3. Iafusco D, Massa O, Pasquino B, Colombo C, Iughetti L, et al. (2012) Minimal incidence of neonatal/infancy onset diabetes in Italy is 1:90,000 live births. Acta Diabetol 49: 405-408.
4. Slingerland AS, Shields BM, Flanagan SE, Bruining GJ, Noordam K, et al. (2009) Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 52: 1683-1685.
5. Metz C, Cavé H, Bertrand AM, Defert C, Gueguen-Giroux B, et al. (2002) Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases. J Pediatr 141: 483-489.
6. Gottschalk ME, Schatz DA, Kaufman DL, Ting GS, et al. (1992) Permanent diabetes without serological evidence of autoimmunity after transient neonatal diabetes. Diabetes Care 15: 1273-1276.
7. Rubio-Cabezas O, Klupa T, Malecki MT; CEED3 Consortium (2011) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 355: 33-333.
8. Flechtnr I, Vaxillaire M, Cavé H, Scharffmann R, Froguel P, et al. (2008) Neonatal hyperglycaemia and abnormal development of the pancreas. Best Pract Res Clin Endocrinol Metab 22: 17-40.
9. Woolley SL, Saranga S (2006) Neonatal diabetes mellitus: A rare but important diagnosis in the critically ill infant. Eur J Emerg Med 13: 349-351.
10. Bin-Abbas B, Al-Mulhim A, Al-Ashwal A (2002) Wolcott-Rallison syndrome in two siblings with isolated central hypothyroidism. Am J Med Genet 111: 187-190.
11. Myers AK, Perroni L, Costigan C, Reardon W (2006) Clinical and molecular findings in IPEX syndrome. Arch Dis Child 91: 63-64.
12. Shield JP (2000) Neonatal diabetes: new insights into aetiology and implications. Horm Res 53 Suppl 1: 7-11.
13. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruijning GJ, et al. (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350: 1838-1849.
14. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, et al. (2004) Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A 101: 17539-17544.
15. Proks P, Girard C, Haider S, Gloyn AL, Hattersley AT, et al. (2005) A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep 6: 470-475.
16. Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, et al. (2007) Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes 56: 1930-1937.
17. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, et al. (2007) Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet 81: 375-382.
18. Masia R, De Leon DD, MacMullen C, McKnight H, Stanley CA, et al. (2007) A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). Diabetes 56: 1357-1362.
19. Murphy R, Schild S, Hattersley AT (2008) Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 4: 200-213.
20. Russo L, Iafusco D, Brescianini S, Nocerino V, Bizzarri C, et al. (2011) Permanent diabetes during the first year of life: multiple gene screening in 54 patients. Diabetologia 54: 1693-1701.
21. Colombo C, Porzio O, Liu M, Massa O, Vasta M, et al. (2008) Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 118: 2148-2156.
22. Babenko AP, Polak M, Cavé H, Busiah K, Czernichow P, et al. (2006) Activating mutations in the ABCB8 gene in neonatal diabetes mellitus. N Engl J Med 355: 456-466.
23. Vaxillaire M, Dechaume A, Busiah K, Cave H, Pereira S, et al. (2007) New ABCB8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 56: 1737-1741.
24. Codner E, Flanagan SE, Ugarte F, Garay a H, Vidal T, et al. (2007) AT-Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days. Diabetes Care 30: e28-e29.
25. Fanciullo L, Iovane B, Gkliati D, Monti G, Sponzilli I, et al. (2012) Sulfonylurea-responsive neonatal diabetes mellitus diagnosed through molecular genetics in two children and in one adult after a long period of insulin treatment. Acta Biomed 83: 56-61.
26. Klupa T, Kowalska I, Wyka K, Skupien J, Patch AM, et al. (2009) Mutations in the ABCB8 (SUR1 subunit of the K(ATP) channel) gene are associated with a variable clinical phenotype. Clin Endocrinol (Oxf) 71: 358-362.
27. Klee P, Bellanné-Chantelot C, Depret G, Llano JP, Paget C, et al. (2012) A novel ABCB8 mutation illustrates the variability of the diabetes phenotypes associated with a single mutation. Diabetes Metab 38: 179-182.
28. Patch AM, Flanagan SE, Boustred C, Hattersley AT, Ellard S (2007) Mutations in the ABCB8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab 9 Suppl 2: 28-39.